It’s being widely reported – and celebrated by experts – that an experimental drug has, for the first time, “unambiguously” slowed the cognitive decline and brain damage in Alzheimer’s patients.
All we really know comes from a drug company press release, and full data is expected to be released at a conference in November – but already esteemed scientists not involved in the trial are calling the results “historic”.
